HomeCompareBNOX vs GIS

BNOX vs GIS: Dividend Comparison 2026

BNOX yields 790.20% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOX wins by $2499878.50M in total portfolio value
10 years
BNOX
BNOX
● Live price
790.20%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2499878.58M
Annual income
$2,001,595,404,407.55
Full BNOX calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — BNOX vs GIS

📍 BNOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOXGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOX + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNOX pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOX
Annual income on $10K today (after 15% tax)
$67,167.13/yr
After 10yr DRIP, annual income (after tax)
$1,701,356,093,746.42/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, BNOX beats the other by $1,701,356,079,881.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOX + GIS for your $10,000?

BNOX: 50%GIS: 50%
100% GIS50/50100% BNOX
Portfolio after 10yr
$1249939.33M
Annual income
$1,000,797,710,359.49/yr
Blended yield
80.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BNOX right now

BNOX
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$6.00
+2270.6% upside vs current
Range: $6.00 — $6.00
Altman Z
-82.3
Piotroski
5/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOX buys
0
GIS buys
0
No recent congressional trades found for BNOX or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOXGIS
Forward yield790.20%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$2499878.58M$79.2K
Annual income after 10y$2,001,595,404,407.55$16,311.42
Total dividends collected$2460392.87M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$6.00$47.42

Year-by-year: BNOX vs GIS ($10,000, DRIP)

YearBNOX PortfolioBNOX Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$89,720$79,020.15$11,504$804.11+$78.2KBNOX
2$758,589$662,588.76$13,371$1,061.65+$745.2KBNOX
3$6,047,418$5,235,727.31$15,723$1,416.15+$6.03MBNOX
4$45,478,990$39,008,252.73$18,735$1,911.16+$45.46MBNOX
5$322,828,490$274,165,970.92$22,660$2,613.51+$322.81MBNOX
6$2,164,251,074$1,818,824,589.26$27,874$3,627.81+$2164.22MBNOX
7$13,711,496,364$11,395,747,714.83$34,947$5,121.52+$13711.46MBNOX
8$82,145,270,460$67,473,969,350.51$44,762$7,369.21+$82145.23MBNOX
9$465,685,208,688$377,789,769,296.29$58,728$10,832.80+$465685.15MBNOX
10$2,499,878,577,704$2,001,595,404,407.55$79,151$16,311.42+$2499878.50MBNOX

BNOX vs GIS: Complete Analysis 2026

BNOXStock

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOX Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this BNOX vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOX vs SCHDBNOX vs JEPIBNOX vs OBNOX vs KOBNOX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.